CUE BIOPHARMA INC (CUE)
US22978P1066 - Common Stock
Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
BOSTON, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of...
Cue Biopharma Announces Pricing of $12.0 Million Public Offering
Cue Biopharma Announces Pricing of $12.0 Million Public Offering
BOSTON, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of...
Cue Biopharma Announces Proposed Public Offering
Cue Biopharma Announces Proposed Public Offering
BOSTON, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of...
Cue Biopharma Announces Proposed Public Offering
Cue Biopharma Announces Proposed Public Offering
BOSTON, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of...
Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Business Officer
Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Business Officer
BOSTON, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of...
Cue Biopharma to Present at The Promise of Interleukin-2 Therapy Conference
Cue Biopharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights
Cue Biopharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights
BOSTON, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of...
CUE Stock Earnings: Cue Biopharma Beats EPS, Beats Revenue for Q2 2024
CUE stock results show that Cue Biopharma beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Cue Biopharma to Host Business Update Call and Webcast
Cue Biopharma Presents Updated Data from Phase 1 Trial of CUE-101 in Recurrent/Metastatic HPV+ Head and Neck Cancer at the 2024 ASCO Annual Meeting
Overall response rate (ORR) of 46% and 12-month overall survival (OS) of 96% in first line (1L) recurrent/metastatic (R/M) HPV+ head and neck squamous cell...
Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences in June 2024
Medical Moonshots: 3 Biotech Stocks Set to Skyrocket
Though risky, investors who buy biotech stocks watch their portfolios skyrocket when their drugs work as intended.
CUE Stock Earnings: Cue Biopharma Beats EPS, Beats Revenue for Q1 2024
CUE stock results show that Cue Biopharma beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
CUE Stock Earnings: Cue Biopharma Beats EPS, Beats Revenue for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Cue Biopharma (NASDAQ:CUE) just reported results for the first quarter of 2024....
Cue Biopharma Reports First Quarter 2024 Financial Results and Recent Business Highlights
Cue Biopharma to Present at the 20th Annual PEGS Boston Summit
Cue Biopharma to Present at the 20th Annual PEGS Boston Summit
BOSTON, May 08, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of...
Cue Biopharma to Participate in Fireside Chat at The Citizens JMP Life Sciences Conference
Cue Biopharma to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Cue Biopharma to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
BOSTON, April 24, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of...